doxapram has been researched along with Neuromuscular Diseases in 1 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Neuromuscular Diseases: A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acute-on-chronic respiratory failure is becoming an increasingly common medical emergency, mostly as a result of exacerbations of chronic obstructive pulmonary disease." | 2.44 | Managing acute on chronic respiratory failure: a guide to non-invasive ventilation. ( Goldring, JJ; Wedzicha, JA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldring, JJ | 1 |
| Wedzicha, JA | 1 |
1 review available for doxapram and Neuromuscular Diseases
| Article | Year |
|---|---|
Managing acute on chronic respiratory failure: a guide to non-invasive ventilation.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Chronic Disease; Cystic Fibrosis; Doxapram; Humans; Midd | 2008 |